articleCellJan 1, 2022HYBRID OA

Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins

Broad Institute · Howard Hughes Medical Institute · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Methods to deliver gene editing agents in vivo as ribonucleoproteins could offer safety advantages over nucleic acid delivery approaches. We report the development and application of engineered DNA-free virus-like particles (eVLPs) that efficiently package and deliver base editor or Cas9 ribonucleoproteins. By engineering VLPs to overcome cargo packaging, release, and localization bottlenecks, we developed fourth-generation eVLPs that mediate efficient base editing in several primary mouse and human cell types. Using different glycoproteins in eVLPs alters their cellular tropism. Single injections of eVLPs into mice support therapeutic levels of base editing in multiple tissues, reducing serum Pcsk9 levels 78%…

No related works found for this paper.

Funding